Core Insights - The core viewpoint of the article is that the power dynamics in China's anti-hair loss market have shifted from traditional daily chemical brands to pharmaceutical companies, driven by a growing consumer base and evolving market demands [4][5]. Market Dynamics - The anti-hair loss market in China has seen a significant transformation, with over 300 million people affected by hair loss, particularly among the 26-35 age group, indicating a shift from a minor issue to a widespread concern [4]. - Pharmaceutical companies, particularly those with OTC pipelines and dermatological resources, have emerged as the primary players in the market, leading to a dual oligopoly dominated by Sanofi's Mandi and Zhendong Pharmaceutical's Dafeixin [4][8]. - The market for anti-hair loss products has reached 5.247 billion yuan in sales within the first ten months of 2025, reflecting a year-on-year growth of over 47% [10][13]. Brand Strategies - Pharmaceutical companies are creating a new narrative of "anti-hair loss = medicine + consumer," leveraging high margins and professional barriers while extending their product lines into daily care categories [5][19]. - Brands like Mandi and Dafeixin are combining pharmaceutical and cosmetic products, promoting them through "scientific anti-hair loss salons" to capture consumer interest [6][9]. Competitive Landscape - Traditional daily chemical brands are struggling, with companies like Bawang reporting a significant decline in profits despite a slight revenue increase, highlighting a structural challenge in the market [8]. - The consumer focus has shifted from "shampoo for hair loss" to "medical treatment and scalp management," indicating a demand for more scientifically-backed solutions [9][10]. Emerging Trends - The average price of anti-hair loss products has risen to over 113 yuan, suggesting consumers are willing to invest more in effective scalp care solutions [13]. - New brands such as EHD and Off&Relax are gaining traction, with EHD leading in sales at 371 million yuan, showcasing a trend towards professional and functional care [16][18]. Future Directions - To compete effectively, beauty brands must transition from traditional narratives to scientific and medical language, focusing on the mechanisms behind hair loss and scalp health [19][23]. - The integration of devices with hair care products is emerging as a trend, with brands like Kérastase introducing scalp care devices that enhance treatment efficacy [25][27]. Conclusion - The anti-hair loss market is evolving into a sector characterized by scientific, medical, and long-term management approaches, with pharmaceutical companies redefining the rules and traditional brands being compelled to adapt [19].

Group 1 - Watsons is planning to go public in Hong Kong and the UK, aiming to raise up to $2 billion, with preparations expected to start in the first half of next year [1][2] - This marks Watsons' third attempt at an IPO, following previous plans in 2014 and 2024, but the current market presents unprecedented challenges [1][2] - The Hong Kong IPO market has significantly recovered since 2025, with new stock financing reaching HKD 216 billion in the first ten months, more than doubling from the previous year [2] Group 2 - The independent listing of Watsons is expected to unlock undervalued asset value for the parent company, CK Hutchison, which currently has a near-zero implied valuation for its unlisted businesses [3] - Listing will provide much-needed funds for Watsons' strategic transformation and help attract and retain talent through equity incentives [3] - Watsons operates 17,000 stores across 31 markets, serving over 6 billion customers annually [3] Group 3 - In the first half of 2025, Watsons' global revenue increased by 8% year-on-year to HKD 98.84 billion, indicating signs of recovery [4] - The European market has become a growth engine, with revenue reaching HKD 60.70 billion, a 10% increase year-on-year, while the Asian market (excluding China) also performed well with a 12% revenue growth [4] - In contrast, Watsons' revenue in China fell by 3% to HKD 6.67 billion, with EBITDA plummeting by 53%, marking six consecutive years of revenue decline in the Chinese market [4] Group 4 - Watsons once thrived in the Chinese market, establishing a strong brand presence and expanding rapidly from 2009, reaching 1,700 stores by 2014 [5] - The company had significant bargaining power with brands, requiring various fees for shelf space, which contributed to its profitability [6] - However, since 2015, Watsons has faced declining sales and store closures, with online channels and new beauty retail formats posing significant challenges [7][9]

Group 1 - The Hong Kong capital market has shown strong performance since 2025, with 88 new IPOs this year and a total fundraising amount exceeding 250 billion HKD, maintaining the top position globally for IPO fundraising [1] - Daily trading volume in Hong Kong has surpassed 33 billion USD, setting a historical high and confirming the recovery outlook from several international financial institutions [1] - Hong Kong's advantages, such as transparent regulations and deep integration with mainland China, have attracted international institutional investors, boosting the IPO market's activity [1] Group 2 - The "A+H" dual listing model has become increasingly active this year, with significant assistance from Baihui Financial Holdings, facilitating multiple A+H listings [2] - Major mainland companies are using Hong Kong as a key bridge to international investors, with notable firms like CATL and Hengrui Medicine successfully listing on the Hong Kong Stock Exchange [2] - The trend of A+H listings indicates that A-share companies are enhancing their global capital reach and that Hong Kong is transforming into an international platform for high-quality Chinese assets [2] Group 3 - Hong Kong continues to play a dual role as a "super connector" and "super value creator," linking Chinese and global markets through its regulatory framework and professional financial services [3] - The Global Financial Centers Index report ranked Hong Kong first in financial technology development, supporting the innovative growth of the capital market [3] - The IPO activities and fundraising scale in Hong Kong are expected to maintain growth in the coming year, driven by the rapid development of AI, green technology, and new consumption sectors [3]

Core Insights - A hair loss treatment product from Mandi International, a subsidiary of Sangfor Pharmaceutical, is set to go public on the Hong Kong Stock Exchange, potentially marking the third IPO for the Liu family [1] - Mandi International holds a significant 57% market share in China's hair loss medication market, driven by its flagship product, Mandi® Minoxidil [1][4] - Despite strong financial performance, Mandi International faces challenges such as product concentration, reduced R&D investment, and increasing competition [1][7] Financial Performance - Mandi International's revenue projections for 2022 to 2024 are 982 million RMB, 1.228 billion RMB, and 1.455 billion RMB, with net profits of 202 million RMB, 441 million RMB, and 309 million RMB respectively [2] - In the first half of 2025, the company reported revenue of 743 million RMB, a 20.2% increase year-on-year, and a net profit of 174 million RMB, up 64.1% [2] - The gross margin for the company has remained high, with figures of 80.3%, 82.0%, 82.7%, and 81.1% from 2022 to 2025 [3] Product Structure - Over 90% of Mandi International's revenue comes from the Mandi® product line, with the core product Mandi® 5% Minoxidil accounting for 91.3% and 91.6% of revenue in 2022 and 2023 respectively [4] - The company is expanding its product line to include other skin care products and is developing a long-acting GLP-1 receptor agonist for weight management, currently in Phase III clinical trials [6] R&D and Marketing - Mandi International's R&D expenses saw a significant drop from 92.2 million RMB in 2024 to 19.5 million RMB in the first half of 2025, raising concerns about its innovation capabilities [7] - In contrast, sales expenses have increased, reaching 374 million RMB in the first half of 2025, which is over 50% of total revenue [9] Market Competition - The hair loss treatment market is becoming increasingly competitive, with major players like Merck and Johnson & Johnson entering the space [12] - Mandi International's core patents are set to expire in 2028, which could lead to a surge in generic products and price competition [12] - The number of registered hair loss shampoos in China has exceeded 400, indicating a crowded market [12] Industry Trends - The global hair loss medication market is projected to reach $2.11 billion in 2024 and $3.175 billion by 2031, with a CAGR of 6.1% [12] - The rising interest in consumer healthcare and the potential for high-margin, self-purchased products are attracting capital market attention [13]

Core Viewpoint - A hair loss treatment product from Mandi International, a subsidiary of 3SBio, is expected to lead to a third IPO for the Liu family, amidst a growing hair loss crisis in China, where over 330 million people are affected, with more than 60% under the age of 35 [2][4]. Financial Performance - Mandi International reported impressive financial data, with revenues projected to reach RMB 9.82 billion, RMB 12.28 billion, and RMB 14.55 billion from 2022 to 2024, and net profits of RMB 2.02 billion, RMB 4.41 billion, and RMB 3.09 billion respectively [6]. - In the first half of 2025, the company achieved revenue of RMB 7.43 billion, a year-on-year increase of 20.2%, and a net profit of RMB 1.74 billion, up 64.1% [6]. Product Concentration - Over 90% of Mandi International's revenue comes from the Mandi® product series, with the core product, Mandi® 5% Minoxidil solution, accounting for 91.3% and 91.6% of revenue in 2022 and 2023 respectively [7][8]. R&D and Marketing Expenditure - Despite strong performance, Mandi International's R&D spending saw a significant drop from RMB 9.22 million in 2024 to RMB 1.95 million in the first half of 2025, raising concerns about its innovation capabilities [11]. - Sales expenses have increased significantly, with over 50% of revenue in the first half of 2025 allocated to sales costs, indicating rising customer acquisition costs in a competitive market [13][14]. Market Competition - The hair loss treatment market is becoming increasingly competitive, with major players like Merck and Johnson & Johnson entering the space. The global market for hair loss treatment is projected to reach USD 2.11 billion in 2024, growing at a CAGR of 6.1% [18]. - Mandi International faces potential risks as some of its core patents are set to expire in 2028, which could lead to a flood of generic products and price wars [18]. Industry Trends - The rising incidence of hair loss among younger demographics is transforming "hair health" into a significant consumer pharmaceutical category, attracting capital market interest [19]. - The company's ability to innovate and diversify its product pipeline will be crucial for its future growth potential, especially in a market that has shown clear demand [19].

Core Viewpoint - The discussion around "celebrity rejuvenation" highlights the ongoing advancements in the global biomedical field, which are bringing humanity closer to extending lifespan through various innovative therapies and technologies [1][2]. Group 1: Advances in Biomedical Technology - Continuous breakthroughs in life sciences are making the ancient human desire for longevity increasingly attainable, pending large-scale commercialization and official endorsement [1]. - Technologies such as stem cells, mitochondrial transplants, and induced pluripotent stem cells (iPSC) are at the forefront of research aimed at extending human life [1][14]. - The approval of the first mesenchymal stem cell product for treating children with steroid-refractory acute graft-versus-host disease (SR-aGVHD) in the U.S. marks a significant milestone in stem cell therapy [23]. Group 2: Market Dynamics and Commercialization - The commercial pathways for longevity-related drugs and therapies are becoming clearer, with a growing demand driving initial implementations in aging delay and specific disease treatments [2]. - The pricing of stem cell therapies in China is significantly lower than similar products in the U.S., making them more accessible [25]. Group 3: Ethical and Social Considerations - There are substantial ethical concerns regarding the commercialization of longevity treatments, particularly the potential for creating a divide where only the wealthy can afford life-extending therapies [22][30]. - The pursuit of longevity by the elite raises questions about the implications for societal dynamics and the potential emergence of a "blood-hunting" class [22][30]. Group 4: Historical Context and Future Outlook - Historical attempts at achieving immortality, from ancient practices to modern biomedical research, reflect a long-standing human fascination with life extension [30]. - The future of longevity research may focus more on treating prevalent diseases rather than solely extending life for a select few, emphasizing the importance of quality of life over mere lifespan [29][30].

Group 1 - The core viewpoint of the article is that the IPO market for consumer companies in Hong Kong is expected to become active again in 2025, following a period of slowdown due to various regulatory and economic factors [2][3] - Since 2021, the capital market for consumer companies has faced challenges due to US-China trade tensions and a regulatory focus on "hard technology," leading to a significant slowdown in the capitalisation process for consumer enterprises [2][3] - In June 2024, a joint announcement by six government departments in China aimed to support quality consumer enterprises in financing through IPOs, which has led to a resurgence in consumer market confidence and activity [2][3] Group 2 - According to PwC data, 34% of new companies listed on the Hong Kong stock exchange in the first half of 2025 were in the retail, consumer goods, and services sectors [4] - From January to October 2025, at least 15 consumer companies successfully listed on the Hong Kong Stock Exchange, covering various sub-sectors such as beverages, food, and personal care [4][6] - The listing pace of consumer companies on the Hong Kong Stock Exchange has accelerated significantly in 2025, with multiple companies going public in concentrated periods throughout the year [6] Group 3 - The food and beverage sector remains the hottest area for IPOs, with companies like Mixue Ice City and Gu Ming representing successful capitalisation in the ready-to-drink beverage market [7] - Despite the overall enthusiasm for consumer stocks, the beauty sector has seen a lack of successful IPOs, with only one company, Yingtong Holdings, managing to list in 2025 [8][9] - As of October 30, 2025, 20 domestic beauty-related companies have initiated the IPO process, with many choosing the Hong Kong Stock Exchange as their primary listing venue [12] Group 4 - The beauty industry faces challenges in successfully listing on the Hong Kong Stock Exchange, with only a few companies completing the process despite a high number of applications [13][14] - Factors contributing to the difficulties include high competition for IPO slots and the need for companies to meet stringent financial and operational criteria set by the exchange [14][15] - Many beauty companies exhibit low R&D investment relative to industry averages, which may hinder their long-term growth potential and ability to sustain cash flow [16][17]

Core Insights - The report highlights Qingmu Technology (青木科技) as a leading expert in full-domain operation services and brand incubation, driven by data and technology [2][4][14] - The company has established a high-synergy business model encompassing operation services, brand incubation, and technical solutions, serving well-known brands across various sectors [2][4][14] - Financial projections indicate significant revenue growth, with expected revenues of 15.1 billion, 19.0 billion, and 23.4 billion yuan for 2025 to 2027, representing year-on-year growth rates of 30.5%, 26.5%, and 23.0% respectively [4][14] Company Overview - Qingmu Technology was founded in 2009 and has focused on e-commerce operation since 2011, building a comprehensive service model that includes operation, brand incubation, and technology solutions [2][14] - The company has a stable ownership structure, with founders holding 39% of the shares, and a management team with over ten years of industry experience [2][14] - Revenue for 2024 and the first half of 2025 is projected at 1.15 billion and 670 million yuan, with year-on-year growth rates of 19.2% and 22.75% respectively [2][14] Competitive Advantages - Qingmu Technology's competitive edge lies in its data, technology, and brand matrix, which collectively enhance its operational value [3][4][14] - The data layer includes services across major platforms like Tmall, JD.com, Douyin, and Xiaohongshu, allowing the company to accumulate extensive user behavior and transaction data [3][14] - The technology layer features proprietary systems such as the Qingling AI platform and CRM, which streamline operations and reduce costs [3][14] Business Model and Growth Strategy - The company is expanding its service model from a single service fee to a combination of service fees, distribution price differences, and equity returns, thus sharing in brand growth [4][14] - Qingmu Technology is diversifying its product categories beyond apparel to include trendy toys, beauty products, health consumer goods, and pet food, enhancing its growth potential [4][14] - The company aims to maintain its status as a top service provider on platforms like Tmall and Douyin while increasing its international operations, particularly in Southeast Asia [4][14] Financial Projections - The report forecasts a steady increase in net profit, with expected figures of 1.31 billion, 1.85 billion, and 2.59 billion yuan for 2025 to 2027, reflecting growth rates of 45.2%, 40.4%, and 40.4% respectively [4][14] - The projected price-to-earnings (PE) ratios for the same period are 50, 35, and 25 times, indicating a favorable valuation outlook [4][14]

Investment Rating - The industry investment rating is "stronger than the market," indicating an expected performance exceeding the market by more than 5% within the next six months [28]. Core Views - The report highlights a recent decline in the consumer sector, with the Shanghai and Shenzhen 300 index dropping by 3.77% from November 17 to November 21, 2025. All sub-sectors within the consumer industry experienced declines, with the most significant drop in consumer services at -6.53% [3][5]. - The report suggests focusing on bottom-fishing opportunities following the recent pullback in the consumer sector [3]. Summary by Sections Consumer Goods - Mass Market - The mass market segment shows high demand in functional beverages and snacks, with a notable performance from brands like Dongpeng Beverage and Salted Fish [3]. - The dairy sector is experiencing a steady recovery, with leading companies likely entering a profit recovery phase [3]. - The restaurant supply chain is stabilizing, with industries like condiments and frozen foods beginning to recover from previous lows [3]. Consumer Goods - Alcohol - Most liquor companies reported a deeper decline in net profits for Q3 2025 compared to Q2 2025, indicating ongoing challenges [3]. - The report identifies three key investment lines: high-end white liquor, mid-range white liquor with national expansion, and local market-focused liquor [3]. Social Services - The social services sector is entering a performance vacuum following Q3 reports, with a focus on companies like China Duty Free and Aimeike that may benefit from policy catalysts and mergers [3]. - The report notes the introduction of snow holidays in regions like Xinjiang, which may boost local tourism [17]. Home Appliances - The home appliance market is experiencing a rational adjustment, with significant declines in retail sales during the Double Eleven shopping festival [15]. - Air conditioning production is expected to drop by 22.6% in December, reflecting ongoing downward pressure in the industry [15]. Textile and Jewelry - The report recommends continued attention to investment opportunities in the gold and jewelry accessories sector, particularly brands with potential for market share growth [3]. Cultural Communication - The report emphasizes the importance of understanding consumer sentiment in niche markets, suggesting that companies in the media sector could benefit from this insight [3].

Summary of China Beauty Expert Call Post 11.11 Events Industry Overview - **Industry**: China Beauty Sector - **Event**: 11.11 Shopping Festival Performance Review - **Date of Call**: November 17, 2025 Key Takeaways 1. **GMV Growth Across Platforms**: - Tmall: Approximately +8% year-over-year (yoy) - Douyin: Approximately +20% yoy - JD: Approximately +15% yoy - PDD: Approximately +12% yoy - Overall GMV growth for the beauty sector: Approximately +14% yoy according to Syntun Data [1][1][1] 2. **Performance of Local Listed Companies**: - Mao Geping (MGP) achieved approximately +60% GMV growth, leading the local brands - Chicmax and Proya maintained strong positions on Douyin and Tmall, respectively - Other local companies faced growth pressures [1][1][1] 3. **International Brands Recovery**: - Most international brands reported over +20% GMV growth, particularly high-end brands like Estee Lauder, Lancome, SK-II, and Shiseido [1][1][1] 4. **Emergence of Local Non-Listed Companies**: - Notable growth from brands such as Chando, Pechoin, Forest Cabin, and Grainrain [1][1][1] 5. **Discount Levels**: - Overall discount levels deepened by 5-8 percentage points yoy compared to the June 18 events [1][1][1] 6. **Preliminary Outlook for 2026**: - US/EU high-end brands expected to maintain growth momentum - Mass brands and Japanese/Korean brands likely to face challenges - High discount levels anticipated to persist [1][1][1] Company-Specific Insights - **Mao Geping (MGP)**: - Enhanced brand equity and unique offline presence expected to drive revenue and earnings CAGR of 31% from 2025 to 2027, outpacing peers' growth of 19% and 16% [1][1][1] - **Chicmax**: - Expected to benefit from the fast growth and local pride trend in China's cosmetics industry, leveraging a successful multi-brand portfolio and strong R&D capabilities [1][1][1] Analyst Preferences in China Beauty Sector - Order of preference: - MGP = Chicmax > Proya > Botanee > Yatsen > Marubi > Jahwa [1][1][1] Additional Notes - Concerns were raised regarding MGP's skincare product pipeline visibility in the mid-term [3][3][3] - Chicmax's KANS brand achieved approximately +30% GMV growth and maintained its position as the No.1 beauty brand on Douyin during the 11.11 events, with self-livestreaming contributing over 70% to GMV [3][3][3] This summary encapsulates the critical insights from the expert call regarding the performance and outlook of the China beauty sector following the 11.11 shopping events.